Approval, Launch and Stable Supply of a Filgrastim Biosimilar
First written in FY2016. 21 of 22 entries say "Restated". Latest entry: FY2023-Q3.
0 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「We are steadily recording revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所, which began sales on 27 November 2019.」
Reaffirming sales of the filgrastim BS drug substance and royalty income from the darbepoetin alfa biosimilar as stable revenue sources. - FY2023-Q2RestatedAnnual report
「We are steadily recording revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所, which began sales on 27 November 2019.」
Reaffirming sales of the filgrastim BS drug substance and royalty income from the darbepoetin alfa biosimilar as stable revenue sources. - FY2023-Q1RestatedAnnual report
「We have been steadily recording revenue from sales of the drug substance for the filgrastim biosimilar for neutropenia jointly marketed in Japan by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar, which was jointly developed with Sanwa Kagaku Kenkyusho Co., Ltd. and began being marketed on 27 November 2019.」
Reaffirming sales of the filgrastim biosimilar drug substance and royalty income from the darbepoetin alfa biosimilar as stable revenue sources. - FY2022-Q3RestatedAnnual report
「We are steadily recording revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所, which began sales on 27 November 2019.」
Reaffirming the existing biosimilars business, including sales of the filgrastim BS drug substance, as a stable revenue base. - FY2022-Q2RestatedAnnual report
「We are steadily recording revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所, which began sales on 27 November 2019.」
Reaffirming the existing biosimilars business, including sales of the filgrastim BS drug substance, as a stable revenue base. - FY2022-Q1RestatedAnnual report
「We are steadily recording revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所, which began sales on 27 November 2019.」
Reaffirming sales of the filgrastim BS drug substance and royalty income from the darbepoetin alfa biosimilar as the existing stable revenue base. - FY2021-Q3RestatedAnnual report
「We are steadily recording revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所, which began sales on 27 November 2019.」
The company continues to sell the drug substance for filgrastim BS and describes its existing biosimilars business as a stable revenue base. - FY2021-Q1RestatedAnnual report
「We are steadily recording revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所, which began sales on 27 November 2019.」
The company continues to sell the drug substance for filgrastim BS and describes its existing biosimilars business, including this product, as a stable revenue base. - FY2020RestatedAnnual report
「The company currently supplies the drug substance for this product to Fuji Pharma Co.,Ltd. on a stable basis, while Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. market it through two brands and two channels.」
Reaffirming the stable supply of drug substance and the two-company, two-brand sales structure for the filgrastim biosimilar. - FY2020-Q3RestatedAnnual report
「Sales of the filgrastim BS treatment for neutropenia by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. are progressing well, and the stability of the company's management is continuing.」
Reaffirming that sales of filgrastim BS are progressing well and that management stability is continuing as a result. - FY2020-Q1RestatedAnnual report
「Sales of the filgrastim BS treatment for neutropenia by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. are progressing well, and the stability of the company's management is continuing.」
Reaffirming that sales of filgrastim BS are progressing well and that management stability is continuing as a result. - FY2019RestatedAnnual report
「The company currently supplies the drug substance for this product to Fuji Pharma Co.,Ltd. on a stable basis, while Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. market it through two brands and two channels.」
Reaffirming the stable supply of drug substance and the two-company, two-brand sales structure for the filgrastim biosimilar. - FY2019-Q2RestatedAnnual report
「Our biosimilars business continues to perform steadily, with sales of the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. progressing well, maintaining stability in our operations.」
Reaffirming that sales of filgrastim BS are progressing well and that management stability is continuing as a result. - FY2019-Q1RestatedAnnual report
「Our biosimilars business continues to perform steadily, with sales of the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. progressing well, maintaining stability in our operations.」
Reaffirming that sales of filgrastim BS are progressing well and that the resulting management stability is continuing. - FY2018RestatedAnnual report
「The company currently supplies the drug substance for this product to Fuji Pharma Co.,Ltd. on a stable basis, while Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. market it through two brands and two channels.」
Reaffirming the stable supply of drug substance and the two-company, two-brand sales structure for the filgrastim biosimilar. - FY2018-Q3RestatedAnnual report
「Against this backdrop, our biosimilars business continues to perform steadily, with sales of the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. progressing well, maintaining stability in our operations.」
Reaffirming that sales of filgrastim BS are progressing well and that the resulting management stability is continuing. - FY2018-Q2RestatedAnnual report
「Sales of the filgrastim BS treatment for neutropenia by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. are progressing well, and the stability of the company's management is continuing.」
The company explains that sales of filgrastim BS are progressing well and that management stability from the existing business is continuing. - FY2017RestatedAnnual report
「The company currently supplies the drug substance for this product to Fuji Pharma Co.,Ltd. on a stable basis, while Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. market it through two brands and two channels.」
The company continues to maintain stable drug substance supplies and a two-company, two-brand sales structure for the filgrastim biosimilar. - FY2017-Q3RestatedAnnual report
「Our biosimilars business continues to perform steadily, with sales of the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. progressing well, maintaining stability in our operations.」
The company explains that sales of filgrastim BS are progressing well and that the stability provided by the existing business is continuing. - FY2017-Q2RestatedAnnual report
「Our biosimilars business continues to perform steadily, with sales of the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. progressing well, maintaining stability in our operations.」
The company explains that sales of filgrastim BS are progressing well and that the stability provided by the existing business is continuing. - FY2017-Q1RestatedAnnual report
「Our biosimilars business continues to perform steadily, with sales of the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. progressing well, maintaining stability in our operations.」
The company explains that sales of the filgrastim biosimilar are progressing well and that management stability from the existing business is continuing. - FY2016First statedAnnual report
「Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd. obtained marketing approval in Japan on 21 November 2012, and the product was launched on 31 May 2013.」
The company is using the filgrastim biosimilar, which has been approved and launched in Japan, as its business foundation, supplying drug substance to Fuji Pharma Co.,Ltd. and marketing the product through two companies and two brands.